Overview of Dr. Tan
Dr. Carlyn Rose Tan is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Sloan Kettering Monmouth. She received her medical degree from Albert Einstein College of Medicine of Yeshiva University and has been in practice 5 years. She is one of 495 doctors at Memorial Sloan Kettering Cancer Center and one of 14 doctors at Memorial Sloan Kettering Monmouth who specialize in Oncology. She has more than 20 publications and over 450 citings.
Office
530 East 74th Street
New York, NY 10021
Education & Training
- Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2017
- Cedars-Sinai Medical CenterResidency, Internal Medicine, 2011 - 2014
- Albert Einstein College of MedicineClass of 2011
Certifications & Licensure
- FL State Medical License 2021 - Present
- CA State Medical License 2012 - 2026
- NJ State Medical License 2020 - 2025
- NY State Medical License 2019 - 2025
- PA State Medical License 2014 - 2024
- NC State Medical License 2020 - 2022
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis Start of enrollment: 2023 Mar 07
Roles: Contact, Principal Investigator
- A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma Start of enrollment: 2022 Oct 27
Roles: Principal Investigator
Publications & Presentations
PubMed
- 88 citationsPhase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.Stefan K. Barta, Jasmine Zain, Alexander W. MacFarlane, Sonali M. Smith, Jia Ruan
Clinical Lymphoma, Myeloma & Leukemia. 2019-06-01 - 107 citationsGPRC5D-Targeted CAR T Cells for Myeloma.Sham Mailankody, Sean M Devlin, Jonathan Landa, Karthik Nath, Claudia Diamonte
The New England Journal of Medicine. 2022-09-29 - 29 citationsComparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, len...Katrina M Piedra, Tim J Peterson, Carlyn Tan, Jennifer S. Orozco, Malin Hultcrantz
British Journal of Haematology. 2021-08-15
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: